|
1
|
Fairfield H, Falank C, Avery L and Reagan
MR: Multiple myeloma in the marrow: Pathogenesis and treatments.
Ann N Y Acad Sci. 1364:32–51. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wallington-Beddoe CT and Mynott RL:
Prognostic and predictive biomarker developments in multiple
myeloma. J Hematol Oncol. 14(151)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Bustoros M, Mouhieddine TH, Detappe A and
Ghobrial IM: Established and novel prognostic biomarkers in
multiple myeloma. Am Soc Clin Oncol Educ Book. 37:548–560.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Afram G, Gran C, Borg Bruchfeld J, Wagner
AK, Hussein A, Alici E and Nahi H: Impact of performance status on
overall survival in patients with relapsed and/or refractory
multiple myeloma: Real-life outcomes of daratumumab treatment. Eur
J Haematol. 105:196–202. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cai Y, Zhao Y, Dai Q, Xu M, Xu X and Xia
W: Prognostic value of the albumin-globulin ratio and
albumin-globulin score in patients with multiple myeloma. J Int Med
Res. 49(300060521997736)2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Qian J, Jin J, Luo H, Jin C, Wang L, Qian
W and Meng H: Analysis of clinical characteristics and prognostic
factors of multiple myeloma: A retrospective single-center study of
787 cases. Hematology. 22:472–476. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen R, Zhang X, Gao C, Luan C, Wang Y and
Chen B: Treatment and prognostic factors for survival in newly
diagnosed multiple myeloma patients with bortezomib and
dexamethasone regimen: A single Chinese center retrospective study.
Cancer Manag Res. 9:373–380. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang X, Duan J, Wen Z, Xiong H, Chen X,
Liu Y, Liao K and Huang C: Are the derived indexes of peripheral
whole blood cell counts (NLR, PLR, LMR/MLR) clinically significant
prognostic biomarkers in multiple myeloma? A systematic review and
meta-analysis. Front Oncol. 11(766672)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Liu S, Shi J, Guo H, Xu F, Wei M, Sun K
and Chen Y: Prognostic significance of the inflammatory index-based
scoring system in patients preliminarily diagnosed with multiple
myeloma in the bortezomib-based chemotherapy era. Cancer Manag Res.
11:9409–9420. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kim DS, Yu ES, Kang KW, Lee SR, Park Y,
Sung HJ, Choi CW and Kim BS: Myeloma prognostic index at diagnosis
might be a prognostic marker in patients newly diagnosed with
multiple myeloma. Korean J Intern Med. 32:711–721. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Szudy-Szczyrek A, Mlak R, Mielnik M,
Szczyrek M, Nowaczyńska A, Homa-Mlak I, Zmorzyński S, Kuśmierczuk
K, Sompor J, Filip A, et al: Prognostic value of pretreatment
neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in
multiple myeloma patients treated with thalidomide-based regimen.
Ann Hematol. 99:2881–2891. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zuo H, Zhai L, Liu X, Gao H and Xu P:
Prognostic significance of neutrophil-lymphocyte ratio in multiple
myeloma patients. Transl Cancer Res. 7:88–96. 2018.
|
|
13
|
Gui L, Wang F, Shi J and Chen B: The
significance of inflammatory markers in the prognosis of newly
diagnosed multiple myeloma patients. Blood. 136 (Suppl
1)(S15)2020.
|
|
14
|
Solmaz S, Uzun O, Acar C, Sevindik OG,
Piskin O, Ozsan HG, Demirkan F, Undar B, Alacacioglu A, Ozcan MA
and Alacacioglu I: Is the platelet-to-lymphocyte ratio a new
prognostic marker in multiple myeloma? J Lab Physicians.
10:363–369. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rajkumar SV: Multiple myeloma: 2016 Update
on diagnosis, risk-stratification, and management. Am J Hematol.
91:719–734. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Azam F, Latif MF, Farooq A, Tirmazy SH,
AlShahrani S, Bashir S and Bukhari N: Performance status assessment
by using ECOG (eastern cooperative oncology group) score for cancer
patients by oncology healthcare professionals. Case Rep Oncol.
12:728–736. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Garderet L, D'Souza A, Jacobs P, van
Biezen A, Schönland S, Kroeger N, Morris C and Hari P: Response
assessment in myeloma: Practical manual on consistent reporting in
an era of dramatic therapeutic advances. Biol Blood Marrow
Transplant. 23:1193–1202. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jung SH, Cho MS, Kim HK, Kim SJ, Kim K,
Cheong JW, Kim SJ, Kim JS, Ahn JS, Kim YK, et al: Risk factors
associated with early mortality in patients with multiple myeloma
who were treated upfront with a novel agents containing regimen.
BMC Cancer. 16(613)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Deftos LJ: Hypercalcemia in malignant and
inflammatory diseases. Endocrinol Metab Clin North Am. 31:141–158.
2002.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Oyajobi BO: Multiple
myeloma/hypercalcemia. Arthritis Res Ther. 9 (Suppl
1)(S4)2007.PubMed/NCBI View
Article : Google Scholar
|
|
23
|
Zagouri F, Kastritis E, Zomas A, Terpos E,
Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos
TP, Michalis E, et al: Hypercalcemia remains an adverse prognostic
factor for newly diagnosed multiple myeloma patients in the era of
novel antimyeloma therapies. Eur J Haematol. 99:409–414.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cheng J, Zhang W, Zhao Y, Li X, Lv R, Li H
and Chen J: Association of serum calcium levels with renal
impairment and all-cause death in Chinese patients with newly
diagnosed multiple myeloma: A cross-sectional, longitudinal study.
Nutr Metab (Lond). 18(19)2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms and consequences. Immunity.
51:27–41. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Arman M, Payne H, Ponomaryov T and Brill
A: Role of Platelets in Inflammation. Intechopen, 2015. https://www.intechopen.com/chapters/48530.
|
|
27
|
Karachaliou N, Pilotto S, Bria E and
Rosell R: Platelets and their role in cancer evolution and immune
system. Transl Lung Cancer Res. 4:713–720. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Mellors P, Binder M, Buadi FK, Lacy MQ,
Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa Y,
et al: Development of thrombocytopenia and survival outcomes in
newly diagnosed multiple myeloma. Blood. 132 (Suppl
1)(S1902)2018.
|
